Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Zai Lab Ltd ( (HK:9688) ) is now available.
Zai Lab Ltd announced the granting of share options and restricted share units under its 2024 Equity Incentive Plan. On June 3, 2025, the company granted options to subscribe for 2,500 American Depositary Shares (ADSs) to one employee and restricted share units covering 4,104 ADSs to three employees. This move is part of Zai Lab’s strategy to align employee incentives with company performance, although the grants do not include performance targets or clawback mechanisms. The compensation committee believes this approach is market competitive and consistent with the company’s customary practices.
The most recent analyst rating on (HK:9688) stock is a Buy with a HK$24.34 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Ltd is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative medicines. It operates in the healthcare industry, primarily targeting oncology, autoimmune disorders, and infectious diseases.
Average Trading Volume: 10,111,075
Technical Sentiment Signal: Buy
Current Market Cap: HK$26.59B
Find detailed analytics on 9688 stock on TipRanks’ Stock Analysis page.